Breaking Down the Barriers to PCSK9 Inhibitor Use in Clinically Appropriate Patients: Bringing Payers and Providers Together to Enhance Outcomes and Access

Breaking Down the Barriers to PCSK9 Inhibitor Use in Clinically Appropriate Patients: Bringing Payers and Providers Together to Enhance Outcomes and Access

On-Demand Webcast

Michael Bloch, MD, FACP, FASH, FSVM, FNLA
Associate Professor, Department of Internal Medicine
University of Nevada School of Medicine
Medical Director, Vascular Care
Renown Institute for Heart and Vascular Health
Reno, Nevada

H. Eric Cannon, PharmD, FAMCP
VP Pharmacy Benefits
Murray, Utah

Intended Learners

Medical directors, pharmacy directors, and other decision makers working in managed care organizations who manage patients with hyperlipidemia.

Learning Objectives

Upon completion of the activity, participants should be able to meet the following tentative educational learning objectives based on the information presented:

  • Review the latest clinical trial data for PCSK9 inhibitors to lower LDL-C and cardiovascular events
  • Assess current evidence for the optimum LDL-C goal for patients with hypercholesterolemia
  • Identify appropriate patients for PCSK9 inhibitor therapy
  • Address payer-and provider-related barriers to appropriate evidence-based use of PCSK9 inhibitors
Activity Overview


This on-demand webcast is available with synchronized slides and audio.

To be eligible for documentation of credit, participants must complete the educational activity, complete the 10-question post-test with a score of 70% or better, and complete the evaluation form. After successful completion of the post-test and evaluation form online at, participants may immediately print their documentation of credit.

Release Date: December 19, 2017
Expiration Date: December 19, 2018
Estimated time to complete: 1 hour

Participants who completed the live version of this activity are not eligible to receive credit for this enduring material.

ACPE Credit Policy

The certificate is not the official record of your participation in the activity. The official record of credit will be the information in CPE Monitor system.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. The reporting function into CPE Monitor will only be available for 60 days after your completion of the activity.  Under ACPE Policy, NACCME will not be able to report your credit to CPE Monitor after this 60 day period.

Hardware/Software Requirements

The evaluation is accessible after the activity via a PC (Windows 7 or newer) or Mac (Mac OS 10.6 or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to


  In support of improving patient care, North American Center for Continuing Medical Education (NACCME) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.



NACCME designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This continuing nursing education activity awards 1 contact hour.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 1 contact hour.

Nurse practitioners may participate in this educational activity and earn a certificate of completing as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.


This activity is approved for 1.0 contact hour (.1 CEU) of continuing pharmacy education (UAN: JA0006201-0000-18-171-H01-P).

This educational activity is a knowledge-based activity.

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Senior Manager, Accreditation and Compliance, NACCME, in writing at 104 Windsor Center Drive, Suite 200, East Windsor, NJ 08520. The Senior Manager, Accreditation and Compliance will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation and Compliance, NACCME, may be made for a second level of review.

Planning Committee

The planning committee comprises Michael Bloch, MD, FACP, FASH, FSVM, FNLA and H. Eric Cannon, PharmD, FAMCP, Donna Brophy, Jennifer Browne, Molly Duda, Jennifer Ilcyn, Michael Kearney, and John Savage, NACCME.

Independent Clinical Reviewer: Peter Oettgen, MD, FACC, FAHA, FACP

Nurse Planner: Susie Seaman, NP, Sharp Rees-Stealy Wound Clinic, San Diego, California

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty has reported the following:

Dr. Bloch: Grant/Research Support—AstraZeneca, Recor; Consultant—Takeda, Amgen, Recor; Speakers’ Bureau—Amgen, Janssen

Dr. CannonConsultantLilly, Sanofi; EmployeeSelectHealth

Ms. Seaman: Advisory Board—Mölnlycke

Ms. Brophy, Ms. Browne, Dr. Cardarelli, Ms. Duda, Ms. Ilcyn, Mr. Kearney, Dr. Ottegen, Mr. Robbin, and Mr. Savage  have disclosed no relevant financial relationships with any commercial interests.

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2017 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

Grant Support

Supported by an educational grant from Amgen, Inc.